Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in severe chronic obstructive pulmonary disease (COPD) to reduce exacerbations
2019-001800-39Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Jul 2019; status: active.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-001800-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001800-39.